Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals reports news about its clinical-stage biotechnology business and its strategy to build a neurology and oncology pipeline. Company updates commonly address anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system, including TPI 287 and Berubicin, as well as clinical-data presentations and regulatory-development planning.
Recurring developments also include executive leadership changes, pipeline prioritization, business-development strategy, financial results, capital-allocation commentary, shareholder voting matters, governance updates and capital-structure disclosures tied to its Nasdaq-listed common stock.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) has announced significant progress in the development of its lead drug candidate, Berubicin, for glioblastoma multiforme (GBM). The company plans to submit an Investigational New Drug (IND) application to the FDA and commence Phase 2 clinical trials in early 2021. CNS has partnered with Worldwide Clinical Trials for trial management and Berry Consultants for statistical guidance. Recently, Berubicin received Orphan Drug Designation from the FDA, providing benefits during development. The company is also advancing its manufacturing capabilities for Berubicin.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced the engagement of Worldwide Clinical Trials as its contract research organization (CRO) for upcoming Berubicin clinical trials. This partnership aims to enhance trial design and execution for Berubicin, the company's lead candidate targeting glioblastoma multiforme. CNS has also enlisted Pharmaceutics International and BSP Pharmaceuticals for Berubicin production, implementing a dual-track strategy to mitigate risks. The company expects to commence Phase 2 trials in adults and a Phase 1 trial in pediatric patients by the end of 2020.
CNS Pharmaceuticals announces a shareholder webinar on August 13, 2020, at 4:30 PM ET. CEO John M. Climaco will discuss business developments, including the progress of CNS's lead candidate Berubicin and novel DNA-binding agent WP1244, alongside their development agreement with WPD Pharmaceuticals for WP1122. CNS specializes in treatments for brain tumors, particularly targeting glioblastoma, considered incurable. The event aims to update shareholders on significant advancements and strategies of the company.
CNS Pharmaceuticals (NASDAQ: CNSP) recognizes Glioblastoma Awareness Day on July 22, 2020, highlighting the urgency of developing treatments for this aggressive cancer. Annually, approximately 10,000 U.S. deaths are due to glioblastoma, with a mere 6.8% five-year survival rate. CNS is advancing Berubicin, a promising therapy shown to improve progression-free survival in 44% of patients in earlier trials. The company plans to initiate a Phase II trial by year-end 2020, having secured manufacturing partnerships to ensure drug availability amidst COVID-19 disruptions.
CNS Pharmaceuticals (NASDAQ: CNSP) announced the shipment of its Active Pharma Ingredient (API) for Berubicin to Pharmaceutics International, Inc. and BSP Pharmaceuticals. This milestone is crucial for the preparations for the upcoming Phase 2 trial for treating glioblastoma multiforme (GBM), expected to commence in Q4 2020. The company has adopted a dual manufacturing strategy to mitigate COVID-19 related risks. CNS holds a global exclusive license for Berubicin, which previously showed a 44% disease control rate in a completed Phase 1 trial.
CNS Pharmaceuticals announced the engagement of Berry Consultants to assist in designing its Phase 2 trial for the lead drug candidate, Berubicin. The CEO, John Climaco, expressed confidence in Berry Consultants' expertise, emphasizing the importance of their innovative approach. Berubicin aims to treat glioblastoma multiforme (GBM), an aggressive brain cancer, following a Phase 1 trial that showed a 44% disease control rate. The Phase 2 trial is expected to commence in Q4 2020, alongside a partner's trials in Poland for pediatric GBM patients.
CNS Pharmaceuticals, focused on treatments for brain cancers, announced that CEO John Climaco will present at the Life Sciences Investor Forum on June 25, 2020, from 12:30 PM to 1:00 PM ET. This online event will allow investors to ask questions in real-time, with an archived webcast available later. CNS is advancing Berubicin, its lead drug candidate, for treating GBM, a fatal brain cancer, and expects to initiate a Phase 2 trial later this year. Investors can pre-register for the event here.